Advertisement


Asaf Maoz, MD, on Pancreatic Surveillance Eligibility Criteria

2025 ASCO Annual Meeting

Advertisement

Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, discusses the sensitivity of age and family history criteria for determining eligibility for pancreatic cancer surveillance among individuals with a hereditary risk for the malignancy (Abstract 10500). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Our study looked at pancreatic cancer surveillance eligibility criteria among individuals who have a genetic risk of pancreatic cancer. Individuals who carry a pathogenic germline variant in a pancreatic cancer predisposition gene have an elevated risk of pancreatic cancer over the lifetime, and when surveillance has been done for these individuals, we have seen that this results in an earlier stage at diagnosis and improved survival compared with historical cohorts. However, not everyone who carries a pathogenic germline variant that predisposes them to pancreatic cancer has been eligible for pancreatic cancer surveillance and eligibility criteria have restricted eligibility based on age and a family history of pancreatic cancer. Our study was meant to look at the proportion of pathogenic germline variant carriers who would have been eligible for pancreatic cancer surveillance at the time of their pancreatic cancer diagnosis, and we leveraged a laboratory cohort to look at this question. We had over 11,000 individuals in the cohort and over 900 individuals who had a pathogenic germline variant that predisposes them to pancreatic cancer. Our results show that the age criteria for pancreatic cancer surveillance eligibility did very well, with over 85% of individuals who had a pathogenic germline variant and developed pancreatic cancer meeting the age eligibility criteria for surveillance. However, the family history criteria did poorly with only 22% of individuals who carry pathogenic germline variants and developing pancreatic cancer meeting the family history criteria when it's applicable. Our results suggest that having a family history of pancreatic cancer needs to be reevaluated as an eligibility criteria for pancreatic cancer surveillance among those who have a genetic risk of pancreatic cancer. We feel that our results support the recent removal of the family history requirement for pancreatic cancer surveillance eligibility for those who have germline pathogenic variants in BRCA2 and ATM.

Related Videos

Breast Cancer

Nicholas C. Turner, MD, PhD, on Treating Emergent ESR1 Mutations in Advanced Breast Cancer

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents findings from the phase III, double-blind ctDNA-guided SERENA-6 trial, which evaluated the combination of camizestrant plus a CDK4/6 inhibitor to treat emergent ESR1 mutations during first-line endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer (LBA4). 

Prostate Cancer

Nicholas D. James, PhD, FRCP, MBBS, on Using AI to Identify Benefit From Prostate Cancer Therapy

Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, describes the use of a multimodal artificial intelligence (AI) model to identify benefit from second-generation androgen receptor pathway inhibitors in patients with high-risk nonmetastatic prostate cancer participating in the STAMPEDE trial (Abstract 5001). 

 

Leukemia

Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, on CLL/SLL: First-Line Zanubrutinib Monotherapy in Patients With del(17p)

Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, of Alfred Hospital and Monash University, reviews results from the 5-year follow-up of arm C of the SEQUOIA trial of treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7011). 

Ruben A. Mesa, MD, on Essential Thrombocythemia: SURPASS-ET Trial

Ruben A. Mesa, MD, of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, presents results from a phase III trial investigating the efficacy of ropeginterferon alfa-2b vs anagrelide for the treatment of essential thrombocythemia (Abstract 6500). 

 

Breast Cancer

Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy

Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer (Abstract 1013). They also discuss findings from the SERENA-6 and EMBER-3 trials, also presented at ASCO 2025, and what all this new data means for the sequencing of endocrine therapy in patients with breast cancer. 

Advertisement

Advertisement




Advertisement